AstraZeneca Pharma India Ltd.

NSE: ASTRAZEN | BSE: 506820

Expensive Star

Download real time

8746.00 231.50 (2.72%)

New 52W High in past week

34,063 NSE+BSE Volume

NSE 17 Apr, 2025 3:57 PM (IST)

21,865

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

AstraZeneca Pharma India Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on AstraZeneca Pharma India Ltd. from all sources in a single place.

AstraZeneca Pharma India Ltd.

15 Apr 2025

8746.00

2.72%

AstraZeneca India surrenders marketing approval of prostate cancer drug

Business Standard

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..

AstraZeneca Pharma India Ltd. is trading above all available SMAs

AstraZeneca Pharma India Ltd.

15 Apr 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And …

BSE India

Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

14 Apr 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations …

BSE India

Please find the enclosed letter of the Company with respect to the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

10 Apr 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

04 Apr 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And …

BSE India

Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

04 Apr 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

28 Mar 2025

8746.00

2.72%

AGM

AstraZeneca Pharma India Ltd - 506820 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot

BSE India

Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

28 Mar 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And …

BSE India

Please find the enclosed intimation of the Company as per the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

22 Mar 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations …

BSE India

Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.

AstraZeneca Pharma India Ltd.

19 Mar 2025

8746.00

2.72%

Company Update

AstraZeneca Pharma India Ltd - 506820 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations …

BSE India

Please find the enclosed letter of the Company in relation to the captioned subject for your reference.

Is AstraZeneca Pharma India Ltd. worth buying?

146 Votes:

Buy 70.55%

Sell 19.86%

Hold 9.59%